about
Guidelines on the Use of Therapeutic Apheresis in Clinical Practice-Evidence-Based Approach from the Writing Committee of the American Society for Apheresis: The Seventh Special Issue.Shiga toxin-producing Escherichia coli O104:H4: an emerging pathogen with enhanced virulenceThrombotic microangiopathy and associated renal disorders.Use of eculizumab for atypical haemolytic uraemic syndrome and C3 glomerulopathies.Management of Shiga toxin-associated Escherichia coli-induced haemolytic uraemic syndrome: randomized clinical trials are needed.Thrombotic microangiopathy in a patient with adult-onset Still's disease.Therapeutic use of a receptor mimic probiotic reduces intestinal Shiga toxin levels in a piglet model of hemolytic uremic syndrome.Neurodevelopmental long-term outcome in children after hemolytic uremic syndrome.Atypical hemolytic uremic syndrome post-kidney transplantation: two case reports and review of the literatureAn international consensus approach to the management of atypical hemolytic uremic syndrome in children.Health-related quality of life and mental health in parents of children with hemolytic uremic syndrome.Indications of underdiagnosis of atypical haemolytic uraemic syndrome in a cohort referred to the Coagulation Unit in Malmo, Sweden, for analysis of ADAMTS13 2007-2012.Subclinical atypical haemolytic uremic syndrome relapse following discontinuation of eculizumab.Different types of glomerulonephritis associated with the dysregulation of the complement alternative pathway in 2 brothers: A case report.Enterohemorrhagic Escherichia coli Hybrid Pathotype O80:H2 as a New Therapeutic ChallengeAdjustment of Eculizumab Dosage Pattern in Patients with Atypical Hemolytic Uremic Syndrome with Suboptimal Response to Standard Treatment Pattern.The complement cascade and renal disease.Atypical Hemolytic Uremic Syndrome: Differential Diagnosis from TTP/HUS and Management.At the Cross Section of Thrombotic Microangiopathy and Atypical Hemolytic Uremic Syndrome: A Narrative Review of Differential Diagnostics and a Problematization of Nomenclature.Influenza-associated thrombotic microangiopathies.Megapneumonia Coinfection: pneumococcus, Mycoplasma pneumoniae, and Metapneumovirus.Atypical HUS caused by anti-complement factor H antibody: a hematologist's perspective.Public Health Research Resulting from One of the World's Largest Outbreaks Caused by Entero-Hemorrhagic Escherichia coli in Germany 2011: A Review.Gemcitabine-induced haemolytic uremic syndrome, although infrequent, can it be prevented: A case report and review of literatureHaemolytic uremic syndrome surveillance in children less than 15 years in Belgium, 2009-2015
P2860
Q30276550-9B1D1DCF-4713-4201-94CE-48517D58A00EQ30411012-8D34CBD0-8B79-4D58-97D2-C7D81A247C31Q33402372-8BC29D2A-D2EE-49F1-A695-9F291D60BC6DQ33403607-E9C0DEF0-3BCD-4D6C-A99D-19F130DCAEBDQ33404149-FD65062E-ED7B-46FC-91FB-DEA1129680E5Q33415416-9FC45053-C4DB-45CB-B2EF-924CCB93DA2CQ33415691-F2568839-D1F6-4E8D-A167-824DB62FFAF8Q33417728-333A32B5-C86A-43BE-A845-848F434D59FEQ33419812-3DF29E08-20F7-4DE2-86A4-91159F0E2C08Q33421861-8358FFF7-B973-405B-A5FB-8B757E097646Q33428663-D920E488-D6F9-44C7-94EB-913849B58949Q33432215-9F4440CE-6B9B-46DD-84F3-38B360F0B20DQ33439105-4294C457-E552-4426-8565-EE5248898425Q33818095-06F1D351-81E2-46A5-A911-1F4C62ECECAEQ37196271-08BFE41B-F651-46E0-9DE1-4704D494150EQ37497101-B6FD8D56-49EC-46ED-A427-2594C64DB0E1Q37502706-C588A6D0-D1DE-4106-BFD0-F5B1DDF7170FQ39112532-7648A6B4-4C6B-4E5A-88CC-2BED5317799DQ39309248-2631875F-DB51-4821-885E-34EF8FCB8425Q40051658-8386F975-C5D0-4E01-BFF6-9956DE1CF180Q41513637-BE42070B-165B-4805-B5D1-C6C5B72FB811Q42678620-A6DDD302-8FC6-4307-BF88-B3A833B473F2Q47295032-3ABD3E47-4C6D-4824-A30B-6309A4DFA622Q58551524-B753CE36-3E33-47A3-AC94-AD090AF0195BQ58798874-6FC51331-D043-44B2-A48D-866A15C8AA4C
P2860
description
2012 nî lūn-bûn
@nan
2012 թուականի Յունուարին հրատարակուած գիտական յօդուած
@hyw
2012 թվականի հունվարին հրատարակված գիտական հոդված
@hy
2012年の論文
@ja
2012年論文
@yue
2012年論文
@zh-hant
2012年論文
@zh-hk
2012年論文
@zh-mo
2012年論文
@zh-tw
2012年论文
@wuu
name
Management of hemolytic uremic syndrome.
@ast
Management of hemolytic uremic syndrome.
@en
type
label
Management of hemolytic uremic syndrome.
@ast
Management of hemolytic uremic syndrome.
@en
prefLabel
Management of hemolytic uremic syndrome.
@ast
Management of hemolytic uremic syndrome.
@en
P2093
P1433
P1476
Management of hemolytic uremic syndrome.
@en
P2093
Chantal Loirat
Jeffrey Saland
Martin Bitzan
P304
P356
10.1016/J.LPM.2011.11.013
P433
P577
2012-01-27T00:00:00Z